Pricing Log in Create free account
Saturday 17 October 2026 Export GILD’s income statement to Excel — free account

Gilead Sciences, Inc.

GILD Healthcare Drug Manufacturers General

Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.

156.19 1.18 −0.75%
Market cap
$195.1B
P/E
0.0×
Fwd P/E
−46.2×
Dividend yield
2.08%
F-score
8/9
Altman Z
4.03
Beneish M
−2.45
Dividend safety
77/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Gilead Sciences, Inc. (GILD) Price to free cash flow

Alert me on Price to free cash flow

As of 16 October 2026, Gilead Sciences, Inc. (GILD) trades at a price to free cash flow of 15.0×. Over the past ten years it has ranged from 5.1× (December 2016) to 20.5× (February 2026); the current reading is higher than 92% of that period. That is below the Drug Manufacturers General industry median of 16.5× and below the Healthcare sector median of 20.2×.

Price to free cash flow, daily

Embed this chart

Annual newest first

Period Price to free cash flow Change
FY2025 16.1× 44.46%
FY2024 11.2× (20.15%)
FY2023 14.0× 9.00%
FY2022 12.8× 52.16%
FY2021 8.4× (13.35%)
FY2020 9.7× (1.80%)
FY2019 9.9× (8.66%)
FY2018 10.9× 26.80%
FY2017 8.6× 40.58%
FY2016 6.1× (15.68%)

Quarterly newest first

Period Price to free cash flow Change
Jun 2026 12.1× (28.29%)
Mar 2026 16.9× 4.79%
Dec 2025 16.1× 7.22%
Sep 2025 15.1× 2.21%
42 more quarters

Against its own ten years

Low 5.1× High 20.5×
Ten-year median 10.6×
Current reading's percentile 92

Price to free cash flow against peers

Company Price to free cash flow
BMY Bristol Myers Squibb Company compare 10.7×
GSK GSK PLC Sponsored ADR compare 13.0×
GILD Gilead Sciences, Inc. 15.0×
PFE Pfizer Inc. compare 16.5×
NVS Novartis AG compare 18.9×
MRK Merck & Co., Inc. compare 22.4×
NVO Novo Nordisk A/S compare 22.6×
AMGN Amgen Inc. compare 24.0×
AZN AstraZeneca PLC compare 40.9×
Drug Manufacturers General industry median 16.5×
Healthcare sector median 20.2×
Market median 14.2×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

More on GILD